[go: up one dir, main page]

MX2019011117A - Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. - Google Patents

Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.

Info

Publication number
MX2019011117A
MX2019011117A MX2019011117A MX2019011117A MX2019011117A MX 2019011117 A MX2019011117 A MX 2019011117A MX 2019011117 A MX2019011117 A MX 2019011117A MX 2019011117 A MX2019011117 A MX 2019011117A MX 2019011117 A MX2019011117 A MX 2019011117A
Authority
MX
Mexico
Prior art keywords
same
antibody
binding fragment
medical use
antigen binding
Prior art date
Application number
MX2019011117A
Other languages
English (en)
Inventor
Zhang Ting
Ye Xin
Tao Weikang
Zhang Lianshan
Gu Jinming
Wang Xiaohua
Yang Liuqing
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2019011117A publication Critical patent/MX2019011117A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención proporciona un anticuerpo B7-H3, un fragmento de unión a antígeno del mismo y un uso médico del mismo. Además, la presente invención describe una composición farmacéutica que comprende el anticuerpo B7-H3 o fragmento de unión a antígeno del mismo, y el uso del mismo como medicamento. En particular, la invención describe un uso de un anticuerpo B7-H3 humano o un fragmento de unión a antígeno del mismo para 10 la fabricación de un medicamento para el tratamiento de una enfermedad o afección asociada a B7-H3.
MX2019011117A 2017-03-31 2018-03-30 Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. MX2019011117A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710206261 2017-03-31
PCT/CN2018/081249 WO2018177393A1 (zh) 2017-03-31 2018-03-30 B7-h3抗体、其抗原结合片段及其医药用途

Publications (1)

Publication Number Publication Date
MX2019011117A true MX2019011117A (es) 2019-11-05

Family

ID=63674249

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011117A MX2019011117A (es) 2017-03-31 2018-03-30 Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.

Country Status (14)

Country Link
US (2) US10899837B2 (es)
EP (1) EP3604337A4 (es)
JP (1) JP7158403B2 (es)
KR (2) KR102662387B1 (es)
CN (1) CN109937212B (es)
AU (1) AU2018243123B2 (es)
BR (1) BR112019019111A2 (es)
CA (1) CA3056474A1 (es)
MX (1) MX2019011117A (es)
MY (1) MY198928A (es)
RU (1) RU2765306C2 (es)
TW (1) TWI796328B (es)
UA (1) UA125593C2 (es)
WO (1) WO2018177393A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019019111A2 (pt) 2017-03-31 2020-05-05 Jiangsu Hengrui Medicine Co., Ltd. anticorpo de b7-h3, seu fragmento de ligação ao antígeno e seu uso médico
WO2019024911A1 (zh) * 2017-08-04 2019-02-07 江苏恒瑞医药股份有限公司 B7h3抗体-药物偶联物及其医药用途
US11270523B2 (en) 2017-11-29 2022-03-08 Sdc U.S. Smilepay Spv Systems and methods for constructing a three-dimensional model from two-dimensional images
US10916053B1 (en) 2019-11-26 2021-02-09 Sdc U.S. Smilepay Spv Systems and methods for constructing a three-dimensional model from two-dimensional images
US11403813B2 (en) 2019-11-26 2022-08-02 Sdc U.S. Smilepay Spv Systems and methods for constructing a three-dimensional model from two-dimensional images
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
MY209065A (en) * 2018-09-30 2025-06-18 Jiangsu Hansoh Pharmaceutical Group Co Ltd Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
WO2020102779A1 (en) 2018-11-16 2020-05-22 Albert Einstein College Of Medicine MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF
TW202033218A (zh) * 2018-12-07 2020-09-16 大陸商江蘇恆瑞醫藥股份有限公司 多特異性蛋白分子
US12056820B2 (en) 2019-05-17 2024-08-06 Sdc U.S. Smilepay Spv Three-dimensional modeling toolkit
US11030801B2 (en) 2019-05-17 2021-06-08 Standard Cyborg, Inc. Three-dimensional modeling toolkit
KR102732027B1 (ko) * 2019-07-09 2024-11-20 주식회사 와이바이오로직스 B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도
US20220332829A1 (en) * 2019-09-16 2022-10-20 Nanjing Sanhome Pharmaceutical Co., Ltd. Anti-b7-h3 antibody and application thereof
WO2021260438A1 (en) * 2020-06-26 2021-12-30 Intocell, Inc. Antibody-drug conjugates comprising anti-b7-h3 antibodies
CN119504997A (zh) * 2021-02-09 2025-02-25 苏州宜联生物医药有限公司 生物活性物偶联物及其制备方法和用途
US20240158505A1 (en) * 2021-03-26 2024-05-16 Theranotics Co., Ltd. B7-h3 antibody or antigen-binding fragment thereof, and use thereof
WO2023155808A1 (zh) 2022-02-16 2023-08-24 苏州宜联生物医药有限公司 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途
US20250188167A1 (en) * 2022-02-25 2025-06-12 Nanjing Probio Biotech Co., Ltd. Antibodies and variants thereof against human b7-h3
JP2025517737A (ja) * 2022-05-18 2025-06-10 ウーシー バイオロジクス アイルランド リミテッド 抗ｂ７ｈ３抗体及びその使用
EP4527415A1 (en) 2022-05-18 2025-03-26 Medilink Therapeutics (Suzhou) Co., Ltd. Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof
WO2024106939A1 (ko) * 2022-11-15 2024-05-23 주식회사 셀랩메드 B7-h3에 특이적으로 결합하는 항체

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US20050002935A1 (en) * 2003-04-17 2005-01-06 Vincent Ling Use of B7-H3 as an immunoregulatory agent
CN101104639A (zh) * 2006-07-10 2008-01-16 苏州大学 抗人b7-h3单克隆抗体的制备及其应用
JP5601836B2 (ja) 2006-11-08 2014-10-08 マクロジェニックス ウエスト， インコーポレイテッド Ｔｅｓ７およびｔｅｓ７に結合する抗体
US20100203035A1 (en) 2007-02-14 2010-08-12 Kwon Eugene D B7-h3 in cancer
WO2010096734A2 (en) 2009-02-20 2010-08-26 John Wayne Cancer Institute B7-h3 antibody coupled bead assay for isolation and detection of circulating tumor cells in body fluids of melanoma and breast cancer patients
HUE045487T2 (hu) * 2010-03-04 2019-12-30 Macrogenics Inc B7-H3-ra reaktív antitestek, immunológiailag aktív fragmenseik és alkalmazásaik
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12013502201A1 (en) 2011-04-25 2014-01-13 Daiichi Sankyo Co Ltd Anti-b7-h3 antibody
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
CA2947660C (en) * 2014-05-29 2021-06-29 Spring Bioscience Corporation Anti-b7-h3 antibodies and diagnostic uses thereof
EP3186277B1 (en) 2014-08-27 2020-10-07 Memorial Sloan Kettering Cancer Center Antibodies, compositions, and uses
JP6613304B2 (ja) * 2014-09-17 2019-12-04 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 抗ｃｄ２７６抗体（ｂ７ｈ３）
BR112019019111A2 (pt) 2017-03-31 2020-05-05 Jiangsu Hengrui Medicine Co., Ltd. anticorpo de b7-h3, seu fragmento de ligação ao antígeno e seu uso médico

Also Published As

Publication number Publication date
US10899837B2 (en) 2021-01-26
CN109937212A (zh) 2019-06-25
AU2018243123A1 (en) 2019-09-26
JP2020515251A (ja) 2020-05-28
BR112019019111A2 (pt) 2020-05-05
AU2018243123B2 (en) 2025-03-13
CA3056474A1 (en) 2018-10-04
TWI796328B (zh) 2023-03-21
KR102662387B1 (ko) 2024-04-29
US20200031934A1 (en) 2020-01-30
RU2765306C2 (ru) 2022-01-28
KR20190134614A (ko) 2019-12-04
CN109937212B (zh) 2022-06-21
RU2019132843A (ru) 2021-04-30
EP3604337A4 (en) 2021-03-10
TW201837056A (zh) 2018-10-16
JP7158403B2 (ja) 2022-10-21
EP3604337A1 (en) 2020-02-05
RU2019132843A3 (es) 2021-08-16
US11680100B2 (en) 2023-06-20
MY198928A (en) 2023-10-02
US20210101984A1 (en) 2021-04-08
WO2018177393A1 (zh) 2018-10-04
UA125593C2 (uk) 2022-04-27
KR20240063177A (ko) 2024-05-09

Similar Documents

Publication Publication Date Title
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
MX2020008977A (es) Formulaciones de anticuerpos de her2 subcutaneas.
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
BR112018074155A2 (pt) anticorpo para lag-3, fragmento de ligação ao antígeno e aplicação farmacêutica do mesmo
CR20190497A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
MX2017006312A (es) Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
MX2019004692A (es) Anticuerpos 4-1bb anti-humano y usos de los mismos.
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
CR20170600A (es) Anticuerpos del factor x1 y métodos de uso
CO2019007823A2 (es) Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo
BR112018009064A2 (pt) anticorpo de pd-l1, fragmento de ligação ao antígeno do mesmo e aplicação médica do mesmo
BR112016029334A2 (pt) produto farmacêutico, uso de um anticorpo, kit, método para tratar um paciente com câncer e métodos e usos de novos produtos
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
CU20160133A7 (es) Anticuerpos anti-mcam y métodos de uso asociados
MX2020010119A (es) Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo.
CL2024000459A1 (es) Tubulisinas y conjugados de proteína-tubulisina.
CO2021008665A2 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
MX2017007595A (es) Inmunoterapia para enfermedad angiogenica.
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
BR112017005313A2 (pt) formação de imagem e terapia para inflamação e infecção direcionadas por hsp90
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CO2020000260A2 (es) Anticuerpos quiméricos para el tratamiento de enfermedades de deposición del amiloide
EA201890457A1 (ru) Комбинации антитела против ox40 и модулятора tlr4 и их применение